CEO Jasbir Seehra outlined the company’s development priorities and partnership plans during a presentation at Oppenheimer’s 36th Annual Healthcare Life Sciences conference, highlighting plans to init ...

Promega Corporation is launching a new live-cell target engagement platform that could close a long-standing gap between biochemical and cellular assays for understudied or difficult-to-interrogate ...

Q4 2025 earnings call recap: royalty revenue up 48%, 2026 guidance reaffirmed, and 23% royalty CAGR to 2030—read key catalysts now.

Discover the critical bioanalytical factors that influence radiopharmaceutical drug development, from assay design to ...

The Radioligand Therapy Market is projected to reach US$13 billion by 2030, growing at an estimated rate of 5%. Key drivers of this growth include the rising incidence of cancers such as prostate ...

Immunotherapy has transformed the treatment landscape for many cancers, yet its efficacy remains highly variable across tumor types and patient populations.

In this month's LCGC Blog, Hayley Brawley and Alexia Kreinbrink explore the challenges facing chromatographers when exploring the complex world of metal speciation. Studying metals in biology is much ...

With big pharma signalling interest in novel RNA-targeted approaches, the term “druggable” is being redefined as technology advances.

Researchers analyzed the thermodynamics of doxepin binding to the histamine H1 receptor. The findings highlight the importance of enthalpy and entropy in GPCR drug design and provide guidance for the ...

G-protein-coupled receptors (GPCRs) are one of the biggest groups of cell surface proteins in the human body, recognizing hormones, neurotransmitters, and drugs.

G-protein-coupled receptors (GPCRs) are one of the largest families of cell surface proteins in the human body that recognize hormones, neurotransmitters, and drugs. These receptors regulate a wide ...